Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:BMEA NASDAQ:EQ NASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.66-10.8%$1.20$0.61▼$3.91$24.27M0.1621.45 million shs830,686 shsBMEABiomea Fusion$1.93-2.5%$1.80$1.29▼$13.07$114.85M-0.13533,113 shs527,598 shsEQEquillium$1.87-6.0%$1.01$0.27▼$2.35$118.41M1.583.05 million shs691,098 shsPLRXPliant Therapeutics$1.59-3.6%$1.56$1.10▼$16.10$97.61M1.43748,385 shs479,113 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-15.74%+69.42%+106.65%-56.20%BMEABiomea Fusion0.00%+0.52%+14.20%-18.22%-74.47%EQEquillium0.00%-2.09%+90.80%+438.90%+120.00%PLRXPliant Therapeutics0.00%-14.52%+0.95%+15.22%-87.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.66-10.8%$1.20$0.61▼$3.91$24.27M0.1621.45 million shs830,686 shsBMEABiomea Fusion$1.93-2.5%$1.80$1.29▼$13.07$114.85M-0.13533,113 shs527,598 shsEQEquillium$1.87-6.0%$1.01$0.27▼$2.35$118.41M1.583.05 million shs691,098 shsPLRXPliant Therapeutics$1.59-3.6%$1.56$1.10▼$16.10$97.61M1.43748,385 shs479,113 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%-15.74%+69.42%+106.65%-56.20%BMEABiomea Fusion0.00%+0.52%+14.20%-18.22%-74.47%EQEquillium0.00%-2.09%+90.80%+438.90%+120.00%PLRXPliant Therapeutics0.00%-14.52%+0.95%+15.22%-87.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 3.00Buy$9.00442.17% UpsideBMEABiomea Fusion 3.17Buy$14.80666.84% UpsideEQEquillium 2.00Hold$1.00-46.52% DownsidePLRXPliant Therapeutics 2.08Hold$8.19414.94% UpsideCurrent Analyst Ratings BreakdownLatest ALLR, BMEA, PLRX, and EQ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/28/2025BMEABiomea FusionJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/11/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $7.008/10/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/8/2025PLRXPliant TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$17.00 ➝ $4.008/6/2025BMEABiomea FusionScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$30.00 ➝ $10.008/6/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.008/5/2025BMEABiomea FusionOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/28/2025ALLRAllarity TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.007/21/2025BMEABiomea FusionD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.007/16/2025BMEABiomea FusionCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $9.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/ABMEABiomea FusionN/AN/AN/AN/A$1.42 per shareN/AEQEquillium$16.55M6.72N/AN/A$0.54 per share3.46PLRXPliant TherapeuticsN/AN/AN/AN/A$5.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-173.31%-102.57%11/13/2025 (Estimated)BMEABiomea Fusion-$138.43M-$3.03N/AN/AN/AN/A-243.95%-140.74%11/4/2025 (Estimated)EQEquillium-$8.07M-$0.56N/AN/AN/A-19.62%-139.56%-90.56%11/12/2025 (Estimated)PLRXPliant Therapeutics-$210.30M-$3.40N/AN/AN/AN/A-73.45%-55.66%11/6/2025 (Estimated)Latest ALLR, BMEA, PLRX, and EQ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025ALLRAllarity Therapeutics-$0.21-$0.15+$0.06-$0.15N/AN/A8/14/2025Q2 2025EQEquillium-$0.14-$0.16-$0.02-$0.16N/AN/A8/7/2025Q2 2025PLRXPliant Therapeutics-$0.62-$0.71-$0.09-$0.71N/AN/A8/5/2025Q2 2025BMEABiomea Fusion-$0.59-$0.51+$0.08-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/ABMEABiomea FusionN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.312.31BMEABiomea FusionN/A3.683.68EQEquilliumN/A1.651.65PLRXPliant Therapeutics0.1412.9912.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%BMEABiomea Fusion96.72%EQEquillium27.05%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%BMEABiomea Fusion18.42%EQEquillium31.60%PLRXPliant Therapeutics8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1014.62 million14.61 millionNot OptionableBMEABiomea Fusion5059.51 million48.55 millionOptionableEQEquillium4059.50 million40.70 millionNot OptionablePLRXPliant Therapeutics9061.39 million56.48 millionOptionableALLR, BMEA, PLRX, and EQ HeadlinesRecent News About These CompaniesNuveen LLC Makes New Investment in Pliant Therapeutics, Inc. $PLRXSeptember 8, 2025 | marketbeat.comCormorant Asset Management LP Purchases Shares of 3,000,000 Pliant Therapeutics, Inc. $PLRXSeptember 6, 2025 | marketbeat.comAllostery Investments LP Makes New $596,000 Investment in Pliant Therapeutics, Inc. $PLRXSeptember 5, 2025 | marketbeat.comPliant Therapeutics, Inc. $PLRX Shares Sold by Redmile Group LLCSeptember 4, 2025 | marketbeat.comPliant Therapeutics, Inc. $PLRX Stock Holdings Lessened by Deutsche Bank AGSeptember 3, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Recommendation of "Hold" by BrokeragesSeptember 3, 2025 | marketbeat.comCW Advisors LLC Takes Position in Pliant Therapeutics, Inc. $PLRXAugust 29, 2025 | marketbeat.comNeedham Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comCiti Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)August 21, 2025 | theglobeandmail.comPliant Therapeutics price target raised to $1.70 from $1.50 at CitiAugust 11, 2025 | msn.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsAugust 7, 2025 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN)July 24, 2025 | theglobeandmail.comPliant Therapeutics Provides Update on BEACON-IPFJune 27, 2025 | globenewswire.comAlnylam, Pliant among stocks yet to face Q2 catalysts: Wells FargoJune 7, 2025 | msn.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALLR, BMEA, PLRX, and EQ Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.66 -0.20 (-10.75%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.66 0.00 (0.00%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Biomea Fusion NASDAQ:BMEA$1.93 -0.05 (-2.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.92 -0.01 (-0.78%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Equillium NASDAQ:EQ$1.87 -0.12 (-6.03%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 09/12/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Pliant Therapeutics NASDAQ:PLRX$1.59 -0.06 (-3.64%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.58 -0.02 (-0.94%) As of 09/12/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
